BridgeBio Reports Third Quarter 2025 Financial Results and Business Updates

Core Insights - BridgeBio Pharma reported a total revenue of $120.7 million for Q3 2025, driven primarily by $108.1 million in U.S. Attruby net product revenue, alongside $4.3 million from royalty revenue and $8.3 million in license and services revenue [1][3][10] - The company has seen significant commercial progress, with 5,259 unique patient prescriptions written by 1,355 unique prescribers as of October 25, 2025, indicating strong adoption of Attruby since its FDA approval in November 2024 [1][2][4] - BridgeBio plans to file New Drug Applications (NDAs) for BBP-418 and encaleret in the first half of 2026, aiming for full approval of these therapies [1][5][8] Commercial Performance - Attruby's launch has been characterized by strong physician adoption and continued growth across all market segments, reflecting its differentiated clinical profile [4][6] - The company reported a significant increase in total revenues, with a $118 million rise compared to the same period last year, primarily due to the commercial success of Attruby [10][11] Pipeline Developments - Positive interim analysis results from the FORTIFY Phase 3 study of BBP-418 showed a 1.8x increase in glycosylated αDG from baseline at 3 months, with sustained improvements at 12 months [1][8] - The CALIBRATE Phase 3 study of encaleret for ADH1 met its primary endpoint, with 76% of participants achieving target calcium levels at Week 24 [1][8] - The PROPEL 3 study of infigratinib for achondroplasia is fully enrolled, with topline results expected in early 2026 [1][8] Financial Overview - As of September 30, 2025, the company had $645.9 million in cash, cash equivalents, and marketable securities, positioning it well to support the commercialization of Attruby and advance its late-stage pipeline [1][9] - Operating costs for Q3 2025 were $265.9 million, reflecting increased investments in support of Attruby's commercial launch [14][15] Key Metrics - The net loss attributable to common stockholders for Q3 2025 was $182.7 million, compared to $162.0 million for the same period in the prior year, with a net loss per share of $0.95 [22][23] - Total revenues for the nine months ended September 30, 2025, were $347.9 million, up from $216.0 million in the prior year [11][12]